By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics firm Response Biomedical today said that revenues for the second quarter rose 17 percent as it trimmed its net loss following a reorganization.

It also disclosed in a document filed with the US Securities and Exchange Commission that its heart failure assay was not cleared by the US Food and Drug Administration for marketing on its Ramp 200 system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.